Home > Technical section > Biotechnology > Biotech companies > Rubicon Genomics

Rubicon Genomics

Thursday 23 February 2012

Website: rubicongenomics.com


- The OmniPLEX amplification kits use proprietary methods for advanced library synthesis and high-yield amplification to prepare samples for sensitive and accurate PCR, microarray, and next-generation sequencing analysis for use in biomedical research and clinical medicine.

- Rubicon’s TransPLEX genomic RNA amplification kits and GenomePLEX® genomic DNA amplification kits are members of Rubicon’s OmniPLEX® family of technologies that are designed and validated to overcome these problems and deliver sufficient quantities of high-quality nucleic acids to enable accurate and consistent analyses.

- FFPE tumor samples are widely used in cancer diagnostics, but they present many challenges for molecular analysis. RNA or DNA extracted from FFPE samples is highly fragmented, and samples often contain only small amounts of usable DNA or RNA that may be insufficient for analysis.


- February 23, 2012 - Rubicon Genomics has inked a clinical supply agreement with molecular diagnostics firm Agendia for its TransPLEX® whole genome RNA amplification technology.

  • Agendia will incorporate Rubicon’s TransPLEX kits into the analysis of FFPE (formalin-fixed, paraffin-embedded) patient samples for use with its Symphony™ suite of breast cancer diagnostics.